GLP-1 Weight Loss in Anchorage: The City That Matches Its State Exactly, and Carries the Whole State's Specialists

Alaska Medicaid's formulary has no weight-loss GLP-1 on it

Alaska expanded Medicaid under the ACA on 9/1/2015. Its Preferred Drug List effective 6/1/2026, a 47-page formulary fetched and parsed directly, lists diabetes-indicated semaglutide, Ozempic and Rybelsus, as preferred and covered, and diabetes-indicated tirzepatide, Mounjaro, as non-preferred with prior authorization or step therapy ¹⁰.

Wegovy, Zepbound, and Saxenda, the weight-loss-labeled brands, do not appear anywhere in the PDL, meaning Alaska Medicaid's formulary process does not cover the anti-obesity indication at all ¹⁰. That sits on top of HRSA's finding that Anchorage's own Medicaid-eligible population, 94,852 people, is a designated primary care shortage population inside the city ⁸.

What GLP-1 care costs in Anchorage today

Belle Medical, an APRN-led medical spa at 2600 Denali St Suite 101, publishes a full self-pay price sheet, confirmed verbatim against the live page on 8/28/2026 ⁹. Compounded semaglutide microdosing runs $500 per three-month supply, about $167 per month, up to 0.75mg weekly. Brand-name Wegovy runs $199/month for the first two months, then $349/month. Oral semaglutide runs $149/month at 1.5 to 4mg up to $299/month at 9 to 25mg.

Compounded tirzepatide runs $1,300 per three-month supply for new patients starting at 5mg weekly, and $600 at 5mg, $850 at 10mg, or $1,100 at 15mg per three-month supply for existing patients, roughly $200 to $433 per month, with microdosing at $600 per three-month supply. Zepbound starts at $299/month and oral Foundayo at $149/month. All of those exclude visit fees and are self-pay only ⁹.

Astra's national price is $68/month for semaglutide and $118/month for tirzepatide on 12-month plans, $816 and $1,416 billed annually. That price is identical in every state Astra serves; there is no city rate.

A shortage designation aimed at Medicaid-eligible residents, inside the state's specialist hub

No whole-population Primary Care HPSA covers Anchorage; HRSA has never designated the general population here as underserved. It does designate the entire borough's Medicaid-eligible population as a Primary Care HPSA, ID 1029282373, score 11, designated 4/7/2020: 94,852 Medicaid-eligible residents, an estimated 31,304 of them underserved, at a 4,478:1 population-to-provider ratio against a 3,000:1 goal, requiring 21.18 additional FTE providers to close ⁸. About 13 facility-level Primary Care HPSAs also sit inside Anchorage, including the Alaska Native Medical Center and Southcentral Foundation tribal-health network, two FQHCs, and two correctional facilities ⁸.

Anchorage is Alaska's de facto specialist hub, since most of the state has no endocrinologist at all and rural and remote Alaskans already travel here for the kind of care a GLP-1 prescription needs. The bench is still thin and directories disagree sharply: Healthgrades lists 6 endocrinology, diabetes, and metabolism specialists in Anchorage while WebMD lists 27, likely counting retired providers or duplicates ¹¹¹². A realistic estimate lands in the single to low double digits for a metro of about 407,000. HRSA issues no endocrinology-specific designation, so this is directory signal, not a federal statistic.

Astra is licensed in all 50 states, Alaska included, so a patient in Anchorage, or one who would otherwise fly into it, sees the same published price as anyone else. See the Alaska GLP-1 overview for statewide context.